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Aim To analyze the effects of glutamatergic agonists and 
antagonists on the activation of the A1 and A2 noradren-
ergic neurons localized in caudal ventrolateral medulla and 
nucleus tractus solitarii, respectively.
Methods Rats were injected with glutamatergic ag-
onists – kainic acid, α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid (AMPA), or N-methyl-D-aspartic 
acid (NMDA), and the brain sections were prepared for 
immunohistochemistry. Before agonist injections, antago-
nists – 6-cyano-7-nitroquinoxaline-2,3-dione or dizocilpine 
were administered. The expression of c-Fos, as the neuronal 
activation marker, and tyrosine hydroxylase (TH), as the 
marker of noradrenergic neurons was assessed with dual 
immunohistochemistry. The percentage of c-Fos-positive 
noradrenergic neurons relative to all TH-positive neurons 
in the respective areas of the brain stem was calculated.
Results All three glutamatergic agonists significantly in-
creased the number of the c-Fos-positive noradrenergic 
neurons in both the A1 and A2 area when compared with 
control animals. Kainic acid injection activated about 57% 
of TH-positive neurons in A1 and 40% in A2, AMPA activat-
ed 26% in A1 and 38% in A2, and NMDA 77% in A1 and 
22% in A2. The injections of appropriate glutamatergic an-
tagonists greatly decreased the number of activated nora-
drenergic neurons.
Conclusion Our results suggest that noradrenergic neu-
rons are regulated and/or activated by glutamatergic sys-
tem and that these neurons express functional glutamate 
receptors.
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Noradrenergic cell groups are neuron groups in the central 
nervous system (CNS) that contain the neurotransmitter nor-
epinephrine (NA, noradrenalin). The central noradrenergic 
system (CNA), which consists of noradrenergic cell groups 
and is located in the brainstem, plays an essential role in the 
pathogenesis of different neurological disorders and in the 
regulation of the memory-related, behavioral, and neuroen-
docrine processes (1-3). In the brain stem, these neurons are 
localized in the brain areas A1 (caudal ventrolateral medulla, 
CVLM), A2 (nucleus tractus solitarii, NTS), A4, A5, A6 (locus 
coeruleus, LC), and A7 (3-5). The noradrenergic neurons in 
the A1 area are distributed ventrolaterally, while the neurons 
in the A2 area are distributed dorsomedially. The A1 and A2 
neurons express tyrosine hydroxylase (TH), a rate-limiting 
enzyme in catecholamine synthesis, but are negative for 
adrenaline-synthesizing enzyme, phenylethanolamine-N-
methyltransferase (PNMT) (6,7). A2 noradrenergic neurons 
are involved in major physiological functions that regulate 
the cardiovascular and respiratory systems, and gustatory, 
hepatic, and renal functions (8,9).
Glutamate is the major excitatory neurotransmitter in the 
mammalian nervous system, which binds and activates 
ionotropic and/or metabotropic glutamate receptors. The 
presence of the glutamatergic terminals has been report-
ed in the brainstem (10-13). Glutamate regulates many 
neuromodulatory processes in the brain stem, including 
the orchestration of the neuroendocrine, behavioral, and 
autonomic functions. Reports showing the glutamatergic 
inputs on noradrenalin neurons and the expression of glu-
tamate receptors by these neurons suggested that gluta-
mate might be involved as a neurotransmitter in the func-
tional regulation of the noradrenergic neurons in the brain 
stem (13-15).
Noradrenergic neurons in the A1 and A2 areas project to 
the hypothalamus and regulate distinct neuroendocrine 
functions (16). A2 group of neurons project to the para-
ventricular nucleus of the hypothalamus (PVN) and are 
implicated in stress regulation (17). A1 and A2 neurons 
control the energy balance (16,18) and food intake (19), 
and play an important role in the regulation of reproduc-
tion through gonadotropin-releasing hormone neurons 
(GnRH) (20). Since these noradrenergic neurons regulate 
neuroendocrine functions and express glutamate receptor 
subunits (21-24), it is important to analyze if these subunits 
form functional glutamate receptor channels. We hypoth-
esized that, if the glutamate receptors on these neurons 
are functional, they, as well as the neurons, can be activat-
ed by the administration of glutamate agonists. In order to 
analyze the activation of these centrally located noradren-
ergic neurons in response to the glutamatergic agonists, N-
methyl-D-aspartic acid (NMDA), kainic acid, and α-amino-
3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA), we 
employed a double-labeling immunohistochemical ap-
proach in which the transient expression of the c-Fos pro-
tein was used as a marker of neuronal activation. We also 
analyzed the blocking effect of glutamate antagonists on 




All animal experiments were carried out in accordance 
with the National Institute of Health Guide for the Care and 
Use of Laboratory Animals and approved by the Animal 
Care and Use Committee of the University. Thirty-six 60-
day-old female Sprague-Dawley rats weighing 200 to 250 
g were used. The rats were maintained at the Bursa Uludag 
University Experimental Animals Breeding and Research 
Center and were housed two per cage in a temperature-
controlled environment (21°C) with a 12:12-hour light/dark 
cycle. All the experiments were carried out between 9:00 
am and 11:00 am.
The animals were divided into nine groups (n = 4 per 
group): kainic acid group (intraperitoneal [ip] injections of 
kainic acid – 2.5 mg/kg in 300 μL distilled water, DW), kain-
ic acid control group (300 μL saline, ip), and kainic acid-6-
cyano-7-nitroquinoxaline-2,3-dione (CNQX) group (2 mg/
kg CNQX in 300 μL DW, ip, 15 minutes before kainic acid 
injection), AMPA group (5 mg/kg AMPA in 750 μL DW, ip), 
AMPA control group (750 μL saline, ip), AMPA-CNQX group 
(2 mg/kg CNQX in 750 μL DW, ip, 15 minutes before AMPA 
injection), NMDA group (100 mg/kg NMDA in 2 mL DW), 
NMDA control group (2 mL saline, ip), and NMDA-dizocil-
pine (1.5 mg/kg MK-801 in 2 mL DW, ip, 15 minutes before 
NMDA injection).
Tissue preparation
Ninety minutes after the injections, the animals were deep-
ly anesthetized and fixed by trans-cardiac perfusion with 
4% paraformaldehyde in phosphate buffer, pH 7.4 (300 mL 
per animal). Brains and brainstems were carefully removed 
and post-fixed overnight in the same fixative. Thirty-mi-
crometer-thick coronal serial sections throughout the 
brain stem were cut with a vibratome and collected 
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into Tris-HCl buffer (0.05 M, pH 7.6). The sections were kept 
in the cryoprotectant solution at -20°C until use.
Immunohistochemistry
Tris-HCl buffer was used for washing, and blocking buffer 
(10% normal horse serum, 0.2% triton X-100, and 0.1% so-
dium azide in Tris-HCl buffer) was used for incubations in 
order to prevent non-specific binding and to dilute the an-
tibodies. Following 2-h incubation in blocking buffer, sec-
tions were transferred into rabbit anti-c-Fos antibody solu-
tion at a dilution of 1:20 000 (Chemicon, Billerica, MA, USA) 
for an overnight incubation. The sections were then ex-
posed to biotin-conjugated donkey anti-rabbit IgG (1:300, 
Jackson Immunoresearch Laboratories, West Grove, PA, 
USA) for 2 h, processed with avidin-biotin complex accord-
ing to the manufacturer’s instructions (ABC Elite Standard 
Kit, Vector Laboratories, Burlingame, CA, USA) for 45 min, 
and stained with diaminobenzidine (DAB, 25 mg) and nick-
el ammonium sulfate (2 g) in the presence of 2 μL hydro-
gen peroxide in 100 mL Tris-HCl buffer. To terminate the 
reaction, sections were transferred to Tris buffer again. The 
c-Fos-immunostained sections were then washed thor-
oughly in Tris-HCl buffer, incubated in blocking buffer, 
and exposed to anti-TH antibody (TH, 1:35,000; lot num-
ber 41K4829; Sigma-Aldrich, St Louis, MO, USA). Following 
overnight incubation, sections were exposed to biotinylat-
ed secondary antibody, then to avidin-biotin reaction as 
described above. DAB was used as the chromogensolu-
tion for the visualization of the immunochemical complex. 
Then, sections were collected onto slides, coded, dried, 
and coverslipped with DPX. Digital photomicrographs of 
stained cells were taken and analyzed using Olympus BX50 
photomicroscope (Olympus, Tokyo, Japan).
Cell counting
Sections were analyzed at 200 × magnification for cell 
counting. All TH-positive cells, with and without c-Fos-pos-
itive nuclei neurons in the CVLM (A1) and NTS (A2) were 
counted bilaterally and blindedly in every fourth section 
between the stereotaxic coordinates of bregma -13.56 
mm- bregma -15.96 mm (25).The percentage of c-Fos-pos-
itive TH neurons was calculated within each group relative 
to all TH-positive cells in the same group.
Statistical analysis
Instead of performing a systematic random sampling, we 
counted all the labeled cells in the studied areas. The pow-
er calculation based on an effect size of 0.8, a standard de-
viation of 12, and an alpha level set at 0.05 showed that the 
required sample size to obtain a power of 0.8 was 4 animals 
per group (36 animals for 9 groups).
Shapiro Wilks test was used for normality testing. The per-
centage of the c-Fos positivity in TH-positive cells is ex-
pressed as mean ± standard deviation. The significance 
of differences between the groups was assessed with 
Kruskal-Wallis test. The level of statistical significance was 
set at P < 0.05. Statistical data analysis was performed by 
IBM SPSS, 23.0 (IBM Corp. Armonk, NY, USA).
RESULTS
Injections of agonists or antagonists did not cause adverse 
reactions or neurological problems, and there was no mor-
tality during the experiments. Drug-induced spontaneous 
neurological effects (eg, shivering) were negligible, and no 
pathological changes were observed in rats’ brains, brain 
stems, and spinal cords after the removal.
TH positivity was visualized by brown reaction product 
with chromogen in the cytoplasm and c-Fos positivity by 
dark-brown/black (nickel intensified chromogen) in the 
nuclei (Figure 1). Double immunohistochemistry for c-Fos 
and TH showed that the glutamatergic system strongly in-
fluenced these two separate but neurochemically related 
neuron groups. All three glutamatergic agonists (kainic 
FIGURE 1. Representative c-Fos-positive and c-Fos-negative 
noradrenergic neurons. The arrow indicates c-Fos positivity 
(dark-blue) in the nucleus of a tyrosine hydroxylase (TH)-pos-
itive (brown) neuron. The arrow-head indicates a representa-
tive c-Fos-negative noradrenergic neuron.
355Gok-Yurtseven et al: Glutamatergic activation of A1 and A2 noradrenergic neurons in the rat brain stem
www.cmj.hr
TAbLE 1. The percentages of c-Fos-positive tyrosine hydroxylase (TH) neurons relative to all TH-positive cells in all groups 
(mean ± standard deviation). P values pertain to the comparison with the kainic acid, α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid (AMPA), or N-methyl-D-aspartic acid (NMDA)-injected groups*
c-Fos expression (%)
A1 noradrenergic neurons P A2 noradrenergic neurons P
Kainic acid control 20.45 ± 10.47 0.011  6.17 ± 3.92 0.011
Kainic acid 57.11 ± 4.90 40.9 ± 19.49
Kainic acid + CNQX 22.94 ± 0.58 0.031 21.36 ± 14.14 0.202
AMPA control 12.44 ± 5.28 0.012  3.21 ± 0.03 0.003
AMPA 26.96 ± 5.55 38.89 ± 3.47
AMPA + CNQX 15.85 ± 6.59 0.077  7.6 ± 0.74 0.239
NMDA control 17.6 ± 2.78 0.014 11.59 ± 6.15 0.087
NMDA 77.93 ± 7.78 25.83 ± 6.57
NMDA + MK801 15.12 ± 1.41 0.024 10.4 ± 6.08
*CNQX – cyano-7-nitroquinoxaline-2,3-dione; MK801 – dizocilpine.
FIGURE 2. Representative images of A1 noradrenergic neurons of the brainstem double-stained for c-Fos and tyrosine hydroxylase 
(TH). The effect of kainic acid (upper set), α -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) (middle set), and N-
methyl-D-aspartic acid (NMDA) (lower set) is shown. Control groups are shown on the left, the agonist injected groups in the middle, 
and antagonist-injected groups on the right.
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acid, AMPA, and NMDA) increased the number of c-Fos+/
TH+ cells in both CVLM and NTS compared with control 
groups (P < 0.05). These effects were also blocked by an-
tagonists that are specific for each agonist (CNQX for kain-
ic acid and AMPA, and MK-801 for NMDA). In A1 neurons, 
NMDA caused the greatest increase in the percentage of 
c-Fos expressing TH-positive neurons (77.93 ± 7.78%). This 
increase was significantly greater when compared with 
the control group (17.6 ± 2.78%, P = 0.014). Kainic acid acti-
vated about 57% of TH-positive neurons (57.11 ± 4.90, sig-
nificantly more than in the control group: 20.45 ± 10.47%, 
P = 0.011), whereas AMPA activated about 26% of neu-
rons (26.96 ± 5.55%, significantly more than in the control 
group: 12.44 ± 5.20%, P = 0.012). In A2 group, both kainic 
acid (40.9 ± 19.49% vs 6.17 ± 3.92%, P = 0.011) and AMPA 
(38.89 ± 3.47% vs 3.21 ± 0.03%, P = 0.003) significantly in-
creased the number of activated neurons compared with 
the control group, but in the NMDA group the increase was 
not significant (P = 0.087). The injections of specific antago-
nists prior to agonists clearly decreased the percentage of 
double-labeled neurons in all groups. However, significant 
difference was only detected in the A1 group when kainic 
acid+CNQX and NMDA+MK-801 were used (Table 1, Figure 
2, Figure 3, and Figure 4)
DISCUSSION
The present study showed that the noradrenergic neurons 
in the A1 and A2 areas of the brain stem were activated by 
glutamatergic agonists. The results also demonstrated that 
glutamatergic antagonists can specifically block this acti-
vation, suggesting that functional glutamate receptors are 
expressed in the noradrenergic neurons of the CVLM and 
NTS. Considering the extensive networks and widespread 
FIGURE 3. Representative images of A2 noradrenergic neurons of the brainstem double stained for c-Fos and tyrosine hydroxylase 
(TH). The effect of kainic acid (upper set), α -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) (middle set), and N-
methyl-D-aspartic acid (NMDA) (lower set) is shown. Control groups are shown on the left, the agonist injected groups in the middle, 
and antagonist-injected groups on the right.
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connections of the noradrenergic system, it can be de-
duced that its altered activity may lead to extensive chang-
es in other brain parts, including the basal brain, forebrain, 
and limbic system. The present study suggests that nora-
drenergic neurons are glutamate-receptive, which is also 
supported by other reports (21-23). In the NTS, both NMDA 
and AMPA receptors are expressed by A2 group of neurons 
(26,27), while in the CVLM, AMPA receptor subunits are syn-
thesized by the A1 group of neurons, which they project to 
the hypothalamus (21).
The central noradrenergic system is connected with hypo-
thalamic pituitary adrenal axis mainly through PVN and its 
corticotropin-releasing hormone neurons (28). Hypotha-
lamic PVN and supraoptic nuclei (SON) have projections 
from A1 and A2 neurons of the brainstem, and magnocel-
lular neurons of these two essential hypothalamic nuclei 
are likely the principal targets of the caudal noradrenergic 
system (29). These projections, which are arising from the 
medullary noradrenergic neurons to the hypothalamus, 
may regulate neuroendocrine functions of the diencepha-
lon, and, as our results revealed, may be under the control 
of glutamatergic neurons. Also it is shown that NA injec-
tions into the PVN stimulate food intake and that the NA 
levels are interrelated with leptin levels, which clearly indi-
cate the relationships among noradrenaline, appetite, and 
energy state (30). Glutamatergic system can contribute to 
these effects as an indirect regulator through the central 
noradrenergic neurons (31,32).
It is well known that neurons in many hypothalamic nuclei, 
including SON and PVN, receive substantial inputs from 
noradrenergic neurons of the brainstem (28). Excitatory 
type connections of the A2 neurons of the NTS to oxyto-
cin neurons and of the A1 neurons of the CVLM to vaso-
pressin neurons have been documented previously (33). In 
addition to these direct projections, A1 neurons are indi-
rectly connected to oxytocin neurons via NTS, and a ma-
jor role in these connections is played by α1 noradrener-
gic receptors (34). Previous studies demonstrated that the 
electrophysiological activation of the A1 neurons excitat-
ed vasopressin secreting neurons of the hypothalamus 
and increased blood pressure (35,36). It is plausible to 
suggest that the signals that arrived to oxytocin and 
FIGURE 4. The percentages of c-Fos-positive tyrosine hydroxylase (TH) neurons relative to all TH-positive cells. The figure summa-
rizes the effects of agonists and antagonists when compared with controls. Agonist injections activated significantly more neurons 
when compared with the control animals. Antagonist injections blocked this activation and the percentage of activated neurons 
decreased significantly. Asterisk indicates the statistical significance when compared with agonist-injected groups. See Table 1 for 
actual P values.
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vasopressin neurons are subject to glutamatergic regula-
tion at the level of the brain stem, since the present study 
showed that glutamate can activate A1 and A2 noradren-
ergic neurons.
The endogenous glutamatergic signals may arrive to the 
brain stem noradrenergic neurons from the periphery. The 
literature shows that the glutamatergic neuronal endings 
make synaptic formations on NTS A2 neurons (37,38). It 
is also reported that the stimulation of the uterine cervix 
is translated into two daily prolactin surges, through the 
activation of PVN-projecting neurons in the A1, A2, and 
LC (39). After the cervical stimulation, an increase in the 
percentage of TH/FG+ double-labeled neurons express-
ing c-Fos was shown in the A1 and LC. These data provide 
evidence of a functional pathway of A1 and LC neurons 
projecting to the PVN that conveys an excitatory signal 
from the periphery, which may be glutamatergic, as the 
present study showed that these neurons can be activat-
ed by glutamate.
In addition, some noradrenergic terminals on the GnRH 
cell bodies also originate ipsilaterally from the caudal por-
tion of the medullary noradrenergic system and may be 
related to GnRH release and sexual behaviors. These con-
nections appear to originate from both A1 and A2 groups 
(40). The present study suggests that some actions of the 
GnRH system may be indirectly regulated by glutamater-
gic system through the connections of central noradren-
ergic system neurons.
Our results showed that the glutamate receptors ex-
pressed by noradrenergic neurons in the A1 and A2 areas 
were functional. The activation of these neurons by glu-
tamatergic challenge was assessed by transient c-Fos ex-
pression, which was used as a neuronal activation marker. 
Our results showed that glutamate agonists can bind and 
activate these receptors, which in turn activates the neu-
rons and possibly results in noradrenaline synthesis and/
or secretion (which is not assessed in the present study). 
This activation suggests that noradrenergic neurons pos-
sess functional glutamate receptors. The effects of the an-
tagonists in terms of decreased number of activated neu-
rons after agonist challenge suggest that the activation 
is specific to glutamate receptors. Since the antagonists 
block the glutamate receptors on noradrenergic neu-
rons, it is plausible that the agonists cannot bind to their 
receptors in order to activate the neurons. Although all 
chemicals used in this study pass the blood-brain bar-
rier, the peripheral injection presents a limitation to 
the study in terms of assessing the agonists’ and antago-
nists’ effects when administered centrally.
Although molecular and synaptic features of the central 
noradrenergic system are not sufficiently investigated, 
and although this system is scattered in the brainstem, 
it is very effectively and significantly linked to important 
CNS structures and regions, including the hypothalamus. 
Our results showed that three different glutamate agonists 
in the brainstem of adult rats activate two separate nora-
drenergic neuronal groups that are known to regulate dis-
crete hypothalamic nuclei. Here, we suggest that some of 
the noradrenergic effects on the hypothalamic neurons 
are regulated by glutamate at the brain stem level. Fur-
ther studies are required to unravel the chemical relations 
between the glutamatergic and noradrenergic systems in 
respect to their locations, distinct projections to the auto-
nomic and limbic structures, as well as their collaborated 
molecular, hormonal, and behavioral functions.
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